Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis

BACKGROUND: Dimethyl fumarate (DMF) is an oral drug approved for Relapsing Multiple Sclerosis (RMS) patients. Grade III lymphopenia is reported in 5–10% DMF-treated patients. Data on lymphocyte count (ALC) recovery after DMF withdrawal following prolonged lymphopenia are still scarce. OBJECTIVES: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucchini, Matteo, Prosperini, Luca, Buscarinu, Maria Chiara, Centonze, Diego, Conte, Antonella, Cortese, Antonio, Elia, Giorgia, Fantozzi, Roberta, Ferraro, Elisabetta, Gasperini, Claudio, Ianniello, Antonio, Landi, Doriana, Marfia, Girolama Alessandra, Nociti, Viviana, Pozzilli, Carlo, Salvetti, Marco, Tortorella, Carla, Mirabella, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179888/
https://www.ncbi.nlm.nih.gov/pubmed/33496861
http://dx.doi.org/10.1007/s00415-021-10412-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179888/
https://www.ncbi.nlm.nih.gov/pubmed/33496861
http://dx.doi.org/10.1007/s00415-021-10412-0

Ejemplares similares